Marijuana occupies an unusual space: parts of it have been refined into FDA-approved prescription drugs, while the plant itself remains federally classified as a Schedule I substance with “no currently accepted medical use.” The honest answer is that some cannabinoid compounds have strong clinical evidence behind them, others show promise but lack rigorous proof, and much of what’s sold in dispensaries hasn’t been tested to pharmaceutical standards. The picture is more nuanced than either side of the debate typically admits.
What the FDA Has Actually Approved
Three cannabinoid medications have full FDA approval, meaning they’ve passed the same clinical trial process as any other prescription drug. Epidiolex contains purified CBD extracted from cannabis plants and is approved for seizures in patients one year and older with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. In a trial published in the New England Journal of Medicine, patients taking CBD experienced a 42% median reduction in drop seizures compared to 17% in the placebo group.
Marinol and Syndros both contain a synthetic version of THC and are approved for treating weight loss and appetite problems in people with AIDS. These drugs go through standardized dosing, purity testing, and safety monitoring that dispensary products do not.
Where the Evidence Is Strongest
Beyond those approved drugs, the best clinical support exists for a handful of conditions. Chronic pain, especially nerve-related pain, is the most common reason people seek medical marijuana. In observational studies, roughly 76% of patients with chronic neuropathic pain reported meaningful improvement. But the picture gets murkier with controlled trials: one randomized study found cannabis reduced pain scores from 7.1 to 6.2 on a 10-point scale, while a placebo brought scores from 7.4 to 5.8, a difference too small to be statistically significant.
Muscle stiffness in multiple sclerosis is another area with solid data. A recent meta-analysis found that cannabis-based treatments produced clinically meaningful reductions in spasticity scores, with larger benefits appearing in studies lasting longer than 24 weeks. Side effects were generally mild: dizziness and dry mouth.
For chemotherapy-induced nausea, the evidence is more complicated than often reported. Of 22 studies comparing cannabinoids to older anti-nausea drugs, just over half found cannabinoids superior. But only one study compared cannabinoids to the modern three-drug regimen that oncologists actually use today. That single study did show a benefit, but it came with notable side effects. Researchers concluded there isn’t enough evidence yet to recommend cannabinoids over current standard treatments for nausea.
How Cannabinoids Work in the Body
Your body already produces its own cannabis-like molecules called endocannabinoids. These bind to two types of receptors scattered throughout your tissues. The first type is concentrated in the brain and nervous system and plays a role in pain signaling, mood, appetite, and memory. The second type is found mainly in immune cells and influences inflammation. THC activates both receptor types directly, which is why it affects pain perception, hunger, and mental state simultaneously. CBD works more indirectly, modifying how those receptors respond and influencing other signaling pathways, which is likely why it reduces seizures without producing a high.
Conditions That Qualify for Medical Programs
State medical marijuana programs typically approve a broad list of conditions. Pennsylvania’s list is representative and includes chronic pain, cancer, epilepsy, multiple sclerosis, PTSD, Parkinson’s disease, Crohn’s disease, anxiety disorders, HIV/AIDS, opioid use disorder, ALS, autism, sickle cell anemia, and terminal illness. The important caveat: qualifying for a state program doesn’t mean the evidence for that condition is equally strong. Some conditions on these lists, like epilepsy and MS spasticity, have substantial trial data. Others, like anxiety or autism, were added based on patient reports and preliminary research rather than large controlled studies.
Risks and Side Effects
Medical cannabis is not risk-free, though serious harms appear uncommon at therapeutic doses. A systematic review of long-term use for chronic pain found that cognitive problems and signs of dependence each occurred in fewer than 1 in 20 patients (very low certainty evidence). Studies lasting longer than 24 weeks reported more adverse events than shorter ones, suggesting that duration of use matters.
One underappreciated risk involves drug interactions. Both THC and CBD interfere with liver enzymes responsible for breaking down many common medications. CBD in particular strongly inhibits an enzyme involved in processing blood thinners, certain anti-seizure drugs, and some anti-inflammatory medications. If you take prescription drugs with a narrow safety margin, adding cannabis products could push those drug levels higher than intended.
Medical Grade vs. Dispensary Products
There’s a meaningful gap between FDA-approved cannabinoid drugs and what you’d buy at a dispensary. Approved medications contain a precise dose of a single active compound. Dispensary products contain dozens of cannabinoids and terpenes in variable ratios, and testing standards differ by state. In New York, for instance, medical cannabis products must meet stricter microbial limits than recreational products: medical products are held to defined thresholds for bacteria and mold, while recreational products only require reporting those results without pass/fail limits. Both categories require testing for pesticides, heavy metals, and mycotoxins, but the overall quality control still falls short of pharmaceutical manufacturing.
How Medical Cannabis Is Dosed
Clinical dosing guidelines developed through expert consensus recommend starting low and increasing gradually. For most patients, the suggested starting point is 5 mg of CBD twice daily, increasing by about 10 mg every two to three days up to 40 mg of CBD per day. If that doesn’t provide enough relief, a small amount of THC (2.5 mg per day) can be added and slowly increased by 2.5 mg every two to seven days. Patients who are older, on multiple medications, or have mental health conditions are advised to start even lower, at 1 mg of THC with weekly increases. Expert consultation is recommended before exceeding 40 mg of THC daily. This careful titration approach is very different from the self-dosing most dispensary patients practice.
The Federal Status Question
Marijuana remains a Schedule I controlled substance under federal law, the most restrictive category. In August 2023, the Department of Health and Human Services formally recommended that the DEA move marijuana to Schedule III, concluding that it has “a currently accepted medical use in treatment in the United States” and a lower potential for abuse than Schedule I or II drugs. The FDA and the National Institute on Drug Abuse both endorsed this recommendation. As of now, however, the DEA has not finalized the rescheduling. A move to Schedule III would not legalize marijuana but would officially recognize its medical value at the federal level and ease restrictions on research.
So is marijuana medicine? Specific cannabinoid compounds, delivered at controlled doses for specific conditions, meet the standard of evidence-based medicine. The broader question of whether smoking or eating a whole-plant product from a dispensary counts as “medicine” in the traditional sense is harder to answer. It can clearly provide symptom relief for many people, but for most conditions, the evidence base is thinner than patients and advocates often assume, and the products lack the standardization we expect from other medications.